Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in multiple myeloma
- Trial result
Multiple myeloma
MK-4002 (BCMA×CD3 trispecific T-cell engager) drives 63% ORR at 12 mg in heavily pretreated RRMM
MK-4002 (formerly HPN217) is an intravenous trispecific T-cell engager that binds BCMA on myeloma cells, CD3 on T cells, and serum albumin to extend its circulating half-life; it was evaluated in a first-in-human,…
NCT04184050 - Trial result
Multiple myeloma
Forimtamig (GPRC5D×CD3 2:1 bispecific) posts 72% ORR at optimized SC dosing—but toxicity caps escalation in RRMM
Forimtamig is a subcutaneous GPRC5D×CD3 T-cell–engaging bispecific antibody using a novel 2:1 format, evaluated in a Phase 1 dose-escalation/backfill study in relapsed/refractory multiple myeloma (RRMM; NCT04557150).…
NCT04557150 - New trial
Multiple myeloma
Phase 2 daratumumab plus teclistamab is compared with DPd or DKd in high-risk, second-line multiple myeloma
This randomized NCI Phase 2 study compares daratumumab-hyaluronidase plus teclistamab with daratumumab/pomalidomide/dexamethasone (DPd) or daratumumab/carfilzomib/dexamethasone (DKd) in high-risk multiple myeloma…
NCT06948084 Exploratory - Trial result
Multiple myeloma
Daratumumab (anti-CD38) cuts progression risk in Japanese high-risk SMM vs monitoring (AQUILA)
Daratumumab is an anti-CD38 monoclonal antibody given as monotherapy; in this exploratory post hoc Japanese subgroup of the Phase 3 AQUILA trial (NCT03301220), patients with high-risk smoldering multiple myeloma…
NCT03301220 - Trial result Spotlight
Multiple myeloma
Teclistamab (BCMAxCD3 bispecific) drives 78% CR and 92% 2-year PFS in high-risk smoldering myeloma
Teclistamab is a BCMA-targeting T-cell–redirecting bispecific antibody tested as a fixed-duration “immune interception” strategy in the randomized Phase 2 ImmunoPRISM trial (NCT05469893) versus…
NCT05469893 - New trial
Multiple myeloma
Phase 1 BCMA–dnTGFβRII armored CAR-T (BCMA CAR + TGF-β resistance)
This Phase 1, single-arm, open-label, dose-escalation/expansion study tests an “armored” BCMA-directed CAR T-cell product in adults with relapsed/refractory multiple myeloma after at least 4 prior lines, including…
NCT05976555 First-in-human - New trial
Multiple myeloma
Phase 1b JNJ-79635322 BCMA×GPRC5D×CD3 T‑cell–redirecting trispecific antibody combos in multiple myeloma
This Janssen Research & Development (Johnson & Johnson) Phase 1b, open-label, multi-part dose-escalation/expansion study is designed to define recommended Phase 2 dose(s) and schedules for JNJ-79635322 (a…
NCT06768489 Exploratory - New trial
Multiple myeloma
Phase 2 ramantamig BCMA×GPRC5D×CD3 trispecific mAb with IL-6R blockade (tocilizumab)
Janssen Research & Development (Johnson & Johnson) is running this Phase 2 randomized, double-blind, placebo-controlled trial to test whether a single prophylactic dose of tocilizumab—an IL-6 receptor–blocking…
NCT07589634 Exploratory - New trial
Multiple myeloma
Phase 2 elranatamab BCMA×CD3 bispecific with IL-6R blockade to prevent CRS
SCRI Development Innovations (part of Sarah Cannon Research Institute/SCRI Oncology Partners) is running this Phase 2, open-label, nonrandomized, single-arm CORE-MM study to test whether outpatient elranatamab…
NCT07637578 Exploratory - New trial
Multiple myeloma
Phase 3 etentamig (ABBV-383) BCMA×CD3 bispecific T‑cell engager plus pomalidomide in 2L+ RRMM.
AbbVie’s Phase 3, multicenter, randomized, open-label study tests whether adding etentamig—an anti-BCMA×anti-CD3 bispecific antibody that redirects T cells to kill BCMA-expressing myeloma cells—improves outcomes when…
NCT07728188 Registrational - New trial
Multiple myeloma
Phase 1 Orca-Q naïve T-cell–depleted allogeneic HSCT to reduce GVHD in high-risk myeloma
This Phase 1 interventional study at UC Davis evaluates ORCA-Q allogeneic hematopoietic stem cell transplantation as a potentially safer, immune-engineered way to deliver graft-versus-myeloma activity in…
NCT07759102 Exploratory - New trial
Multiple myeloma
Feasibility/Early Phase 1 iberdomide (CC-220) cereblon E3-ligase modulator primes T cells
This single-site feasibility study tests whether a 28-day “priming” cycle of iberdomide before leukapheresis can improve T-cell fitness and, downstream, CAR-T expansion kinetics in relapsed/refractory multiple…
NCT07727668 Exploratory - New trial
Multiple myeloma
Phase 4 linvoseltamab BCMA×CD3 bispecific with prophylactic tocilizumab IL-6R blockade
Regeneron Pharmaceuticals is running this Phase 4, single-arm, multicenter outpatient study testing whether giving tocilizumab prophylactically before the first linvoseltamab dose can reduce cytokine release syndrome…
NCT07609940 Exploratory - Trial result
Multiple myeloma
Linvoseltamab (BCMA×CD3 bispecific) shows sustained HRQoL gains (pain/fatigue) in triple-class–exposed R/R myeloma
Linvoseltamab is an off-the-shelf T-cell–engaging BCMA×CD3 bispecific antibody evaluated in LINKER-MM1 (Phase I/II; NCT03761108) in triple-class–exposed relapsed/refractory multiple myeloma (n=117; median follow-up…
NCT03761108 - Trial result Spotlight
Multiple myeloma
Teclistamab (BCMA×CD3 bispecific) drives 76.9% ORR and 25.1-mo mPFS in TCE-RRMM (China)
Teclistamab is a subcutaneous BCMA×CD3 T-cell–redirecting bispecific antibody evaluated in the MajesTEC-1 China cohort with 27.2 months’ follow-up in triple-class exposed RRMM (n=26), dosed 1.5mg/kg weekly with an…
NCT03145181 - Trial result
Multiple myeloma
Linvoseltamab (BCMA×CD3 bispecific) maintains ~63–74% ORR in frail RRMM patients in LINKER-MM1
Linvoseltamab is a human BCMA×CD3 T-cell–engaging bispecific antibody evaluated at the 200mg dose in the Phase 1/2, single-arm LINKER-MM1 study (NCT03761108) in heavily pretreated relapsed/refractory multiple…
NCT03761108 - Trial result
Multiple myeloma
Indefinite lenalidomide (IMiD) maintenance fails to improve OS vs 2-year fixed-duration in standard-risk, non-transplant NDMM
Lenalidomide is an oral immunomodulatory drug (IMiD) commonly used as maintenance “until progression” after frontline proteasome inhibitor–lenalidomide induction in transplant-ineligible NDMM; ENDURANCE (Phase 3;…
NCT01863550 - Trial result Spotlight
Multiple myeloma
Linvoseltamab (BCMA×CD3) tops elranatamab on ORR/≥CR in unanchored MAIC of TCE RRMM
Linvoseltamab is an off-the-shelf BCMA×CD3 T-cell–engaging bispecific antibody compared here with elranatamab, another BCMA×CD3 bispecific, using an unanchored matching-adjusted indirect comparison across LINKER-MM1…
NCT03761108 - Trial result Spotlight
Multiple myeloma
Talquetamab (GPRC5D×CD3) + daratumumab ± pomalidomide sharply improves 24-mo PFS in RRMM
Talquetamab is a GPRC5D×CD3 T-cell–redirecting bispecific antibody, combined here with daratumumab, an anti-CD38 monoclonal antibody, with or without pomalidomide, an immunomodulatory agent. In the Phase 3…
NCT05455320 - Trial result
Multiple myeloma
D-VRd doubles sustained MRD negativity vs VRd in transplant-ineligible/deferred NDMM
Daratumumab is an anti-CD38 monoclonal antibody added to bortezomib/lenalidomide/dexamethasone to create a quadruplet regimen for newly diagnosed multiple myeloma patients who are transplant-ineligible or…
NCT03652064 - New trial Spotlight
Multiple myeloma
Phase 3 linvoseltamab BCMA×CD3 bispecific antibody versus daratumumab anti-CD38 in high-risk SMM.
This Phase 3, randomized, open-label study (LINKER-SMM2) tests whether Regeneron’s linvoseltamab-gcpt—an off-the-shelf T-cell–engaging bispecific monoclonal antibody that binds BCMA on plasma cells and CD3 on T…
NCT07393282 Registrational - Trial result Spotlight
Multiple myeloma
DaraKPd (anti-CD38 mAb + proteasome inhibitor + IMiD) delivers 38.3-mo mPFS in CD38-naïve RRMM
Daratumumab (anti-CD38 monoclonal antibody) combined with carfilzomib (proteasome inhibitor), pomalidomide (IMiD), and dexamethasone (DaraKPd) was evaluated in a phase 2 MMRC study in relapsed/refractory multiple…
NCT01665794 - Trial result Spotlight
Multiple myeloma
Durcabtagene autoleucel (PHE885), a rapid-manufactured BCMA CAR-T, posts 98% ORR and 55% sCR in r/r multiple myeloma
Durcabtagene autoleucel (also known as PHE885) is an autologous BCMA-directed CAR-T made on a rapid manufacturing platform intended to preserve stem-like T-cell features. In Part A of a Phase 1, dose-escalation study…
NCT04318327 - Trial result
Multiple myeloma
Daratumumab (CD38 mAb) boosts depth of response across age/frailty in TIE NDMM (MAIA/CEPHEUS)
Daratumumab is an anti-CD38 monoclonal antibody added to immunomodulatory backbone Rd (MAIA; DRd vs Rd; n=368 vs 369) or to proteasome-inhibitor triplet VRd (CEPHEUS; DVRd vs VRd; n=144 vs 145) in…
- Trial result
Multiple myeloma
Isa SC (on-body injector) + VRd Cuts Infusion Reactions and Neuropathy vs IV Isa-VRd, with Similar ≥VGPR in Ti NDMM (8-mo follow-up)
Isatuximab (anti-CD38 monoclonal antibody) + VRd was given either subcutaneously via an on-body injector (Isa OBI VRd; ISASOCUT Phase 2, n=74; weekly bortezomib after C1) or intravenously (Isa IV VRd; IMROZ Phase 3,…
- Trial result
Multiple myeloma
Daratumumab (CD38 mAb) + Rd Extends PFS to 61.9mo and Improves OS in MAIA NDMM
Daratumumab is an anti-CD38 monoclonal antibody added to lenalidomide (IMiD) + dexamethasone (D-Rd) and tested vs Rd in the Phase 3, randomized MAIA trial (NCT02252172) in transplant-ineligible newly diagnosed…
NCT02252172 - Trial result
Multiple myeloma
Ciltacabtagene autoleucel (cilta-cel) BCMA CAR-T delivers durable 30-month PFS/OS—even in high-risk cytogenetics with ≥PR bridging response
Ciltacabtagene autoleucel (cilta-cel) is an autologous anti-BCMA CAR-T cell therapy evaluated in CARTITUDE-4 (Phase 3; NCT04181827) for lenalidomide-refractory multiple myeloma after 1–3 prior lines; this as-treated…
NCT04181827 - Trial result
Multiple myeloma
Belantamab mafodotin (BCMA ADC) + VRd in DREAMM-9 delivers ≥83% ORR in transplant-ineligible NDMM, with dose-intensity–driven depth vs ocular toxicity tradeoff
Belantamab mafodotin (belamaf) is an anti-BCMA antibody–drug conjugate combined here with bortezomib/lenalidomide/dexamethasone (VRd) as BVRd in the DREAMM-9 Phase 1 dose/schedule optimization study in…
NCT04091126 - Trial result
Multiple myeloma
Talquetamab (GPRC5D×CD3) + teclistamab (BCMA×CD3) lands on Q2W RP2R with 61.1% ORR and 44.4% ≥CR in extramedullary MM
Talquetamab (Tal), a first-in-class GPRC5D-targeting T-cell–redirecting bispecific antibody, was combined with teclistamab (Tec), a first-in-class BCMA-targeting T-cell–redirecting bispecific, in the RedirecTT-1…
NCT04586426 - New trial
Multiple myeloma
Phase 2 infliximab TNF-α inhibitor prophylaxis with BCMA×CD3/GPRC5D×CD3 bispecifics in R/R myeloma
This Phase 2 supportive-care study tests whether prophylactic infliximab (a TNF-α–neutralizing monoclonal antibody) given 2–4 hours before treatment can reduce cytokine release syndrome (CRS) and related…
NCT07657312 Exploratory
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.